A new study in France suggests that treating PATIENTS with COVID-19 with a combination of antimalarial drugs and antibiotics may be an effective weapon against the new coronavirus. The study, published in the International Journal of Antimicrobials, was prescribed earlier this month by researchers to patients with the antimalarial drug hydroxychloroquine and the antibiotic azithromycin.
“Patients diagnosed with COVID-19 in France were included in a one-arm programme from early March to 16 March, receiving 600 mg of hydroxychloroquine per day and testing their nasopharyngeal swabs daily for viral load in hospital settings,” the researchers said in the report. Based on their clinical performance, azithromycin is added to the treatment. “
Untreated patients from another centre and patients with non-treatment of COVID-19 were used as negative controls. “On the sixth day after joining, the presence or failure of the virus will be considered the final diagnosis,” the researchers explained. “
Six patients in the study were asymptomatic, 22 had upper respiratory tract infection symptoms, and 8 had symptoms of lower respiratory tract infection. The researchers treated 20 cases in the study. These cases showed a significant reduction in the carrying of the virus after D6-post integration compared to the control group, and the average carrying time was much lower than in patients not treated in the literature.
The researchers added: “Adding azithromycin to hydroxychloroquine significantly improves the virus removal rate. Although the sample size was small, our study showed that hydroxychloroquine therapy was significantly associated with a decrease or disappearance of viral load in patients with COVID-19, while azithromycin reinforced its effects. “
The study was led by Philippe Gautret and Jean-Christophe Lagier of the Institute of Infections at the University of Marseille and Aix-Marseille.
Dr. Mehmet Oz also said recently that he was optimistic about the French study, explaining: “These drugs are very effective in reducing the viral load of COVID-19 in patients with coronaviruses.” If this is true, we can actually make the virus behave more like an influenza virus. “